Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;56(3):1606-8.
doi: 10.1128/AAC.06064-11. Epub 2012 Jan 3.

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

Premavathy Levasseur  1 , Anne-Marie Girard, Monique Claudon, Herman Goossens, Michael T Black, Kenneth Coleman, Christine Miossec
Affiliations

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

Premavathy Levasseur et al. Antimicrob Agents Chemother. 2012 Mar.

Abstract

The β-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates. Avibactam offered efficient protection from hydrolysis since 94% of isolates were susceptible to ceftazidime when combined with 4 μg/ml avibactam, compared with 65% susceptible to ceftazidime alone. Ceftazidime-avibactam also demonstrated better antipseudomonal activity than imipenem (82% susceptibility), a common reference treatment.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Percent cumulative frequency of susceptible P. aeruginosa strains. The susceptibility of the P. aeruginosa clinical panel (n = 126) to various antibiotics is shown as percent cumulative frequency at concentrations ranging from 0.125 to 256 μg/ml for ceftazidime (CAZ), ceftazidime-avibactam (CAZ + AVI), imipenem (IPM), aztreonam (ATM), and piperacillin-tazobactam (PIP/TZB).
See this image and copyright information in PMC

References

    1. Bonnefoy A, et al. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410–417 - PubMed
    1. Clinical Laboratory Standards Institute 2011. Performance standards for antimicrobial susceptibility testing; twenty-first international supplement, vol 31, no 1. M100-S21 Clinical Laboratory Standards Institute, Wayne, PA
    1. Lister PD, Wolter DJ, Hanson ND. 2010. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582–610 - PMC - PubMed
    1. Mushtaq S, Warner M, Livermore DL. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother. 65:2376–2381 - PubMed
    1. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633–1641 - PMC - PubMed

MeSH terms